StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sangamo Therapeutics's free cash flow for the twelve months ending Mar 31, 2026 was -$90.46M. For fiscal 2025 it was -$97.31M. The highest annual figure on record is $155.16M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$97.31M–
FY2024Dec 31, 2024-$67.41M–
FY2023Dec 31, 2023-$246.00M–
FY2022Dec 31, 2022-$243.80M–
FY2021Dec 31, 2021-$256.53M-265.3%
FY2020Dec 31, 2020$155.16M–
FY2019Dec 31, 2019-$165.08M–
FY2018Dec 31, 2018-$6.52M-187.7%
FY2017Dec 31, 2017$7.43M–
FY2016Dec 31, 2016-$66.62M–
FY2015Dec 31, 2015-$36.13M–
FY2014Dec 31, 2014-$6.30M–
FY2013Dec 31, 2013-$19.91M–
FY2012Dec 31, 2012-$8.81M–
FY2011Dec 31, 2011-$26.47M–
FY2010Dec 31, 2010-$24.63M–
FY2009Dec 31, 2009-$6.41M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$19.30M–
Q4 FY2025Dec 31, 2025-$24.42M–
Q3 FY2025Sep 30, 2025-$28.56M-345.3%
Q2 FY2025Jun 30, 2025-$18.18M–
Q1 FY2025Mar 31, 2025-$26.15M–
Q4 FY2024Dec 31, 2024-$3.50M–
Q3 FY2024Sep 30, 2024$11.64M–
Q2 FY2024Jun 30, 2024-$26.88M–
Q1 FY2024Mar 31, 2024-$48.66M–
Q4 FY2023Dec 31, 2023-$53.21M–
Q3 FY2023Sep 30, 2023-$50.04M–
Q2 FY2023Jun 30, 2023-$66.25M–
Q1 FY2023Mar 31, 2023-$76.50M–
Q4 FY2022Dec 31, 2022-$64.52M–
Q3 FY2022Sep 30, 2022-$58.03M–
Q2 FY2022Jun 30, 2022-$59.43M–
Q1 FY2022Mar 31, 2022-$61.81M–
Q4 FY2021Dec 31, 2021-$55.57M–
Q3 FY2021Sep 30, 2021-$64.63M-322.4%
Q2 FY2021Jun 30, 2021-$59.83M-138.1%
Q1 FY2021Mar 31, 2021-$76.50M–
Q4 FY2020Dec 31, 2020-$8.31M–
Q3 FY2020Sep 30, 2020$29.06M–
Q2 FY2020Jun 30, 2020$157.07M–
Q1 FY2020Mar 31, 2020-$22.67M–
Q4 FY2019Dec 31, 2019-$27.60M–
Q3 FY2019Sep 30, 2019-$43.01M–
Q2 FY2019Jun 30, 2019-$43.38M-136.4%
Q1 FY2019Mar 31, 2019-$51.10M–
Q4 FY2018Dec 31, 2018-$68.20M–
Q3 FY2018Sep 30, 2018-$36.86M–
Q2 FY2018Jun 30, 2018$119.29M+116.6%
Q1 FY2018Mar 31, 2018-$20.75M–
Q4 FY2017Dec 31, 2017-$17.72M–
Q3 FY2017Sep 30, 2017-$16.39M–
Q2 FY2017Jun 30, 2017$55.08M–
Q1 FY2017Mar 31, 2017-$13.55M–
Q4 FY2016Dec 31, 2016-$11.99M–
Q3 FY2016Sep 30, 2016-$17.73M–
Q2 FY2016Jun 30, 2016-$16.28M–

More Sangamo Therapeutics figures

See a number that looks wrong?